CPR builds on the proprietary antibody engineering technology developed by the Chugai Group in order to achieve our goals.

Switch Antibody

Switch-Ig is an antibody that specifically binds to the target antigen in the tumor microenvironment without detectable binding to the antigen in plasma and normal tissue. Switch-Ig technology transforms undruggable targets into druggable targets and enables more effective and safer antibody therapeutics in cancer immunotherapy.

< Back